By Kelly Gooch
Eleven diabetes patients are suing several drug companies for alleged collusion on insulin pricing, reports The Washington Post.
The lawsuit was filed Monday in U.S. District Court in Massachusetts against Indianapolis-based Eli Lilly, French pharmaceutical company Sanofi and Danish drugmaker Novo Nordisk. The suit claims the companies systematically increased insulin list prices for years in an alleged fraudulent-pricing scheme that left patients with “crushing out-of-pocket expenses,” according to the article. The companies, the lawsuit says, increased the insulin list prices to expand their discounts without lowering the overall price tag, according to the report.